SLC5A2 and hydrops fetalis: We observed that 1) SGLT-2 inhibitors reduced the risk of hospitalization for HF; 2) SGLT-2 inhibitors reduced NT-proBNP levels; and 3) SGLT-2 inhibitors improved exercise capacity and QOL.